Jarmila Kruseová

Charles University — Czech Republic

Medicine · Health Sciences

18h-index1.8kcitations99works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(34), Childhood Cancer Survivors' Quality of Life(27), Cancer, Lipids, and Metabolism(25), Cancer, Hypoxia, and Metabolism(20), Acute Lymphoblastic Leukemia research(14)

Publications97 total

Precocious puberty in a thirteen-month-old toddler
Česko-slovenská pediatrie·2025Open Access
Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group
Journal of Clinical Oncology·2025· 4 citedOpen Access
Does Motherhood Increase the Risk of Developing Subsequent Malignant Neoplasms after Childhood Cancer Treatment?
SSRN Electronic Journal·2025Open Access
Interindividual variation in ovarian reserve after gonadotoxic treatment in female childhood cancer survivors – a genome-wide association study: results from PanCareLIFE
Fertility and Sterility·2024· 1 citedOpen Access
Implementation of the Short-Form 36 (SF-36) in childhood cancer survivors: An analysis on measurement properties across 5 European countries
2024· 2 citedOpen Access
Parenthood for childhood cancer survivors: unfounded fear of cancer development in offspring and related health behaviors
Frontiers in Psychology·2024· 3 citedOpen Access
Supplementary Table S4 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Statistics S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Figure S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Data S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Study Protocol S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Figure S3 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Data S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Figure S4 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Data S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Table S3 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Data from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Figure S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Statistics S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
Supplementary Table S3 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Tomáš Kepák(23), Julianne Byrne(22), Uta Dirksen(21), Marry M. van den Heuvel‐Eibrink(19), Leontien C.M. Kremer(19), Jeanette Falck Winther(17), Desiree Grabow(17), Eline van Dulmen‐den Broeder(16), Peter Kaatsch(16), Claudia E. Kuehni(15), Andreas Ranft(14), Melanie Kaiser(14), Gabriele Calaminus(12), Claire Berger(12), Oliver Zolk(12), Antoinette am Zehnhoff‐Dinnesen(11), Anja Borgmann‐Staudt(11), Eva Clemens(11), Claudia Spix(11), Thorsten Langer(11)